308430
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clin… Read more
308430 (308430) - Total Liabilities
Latest total liabilities as of March 2025: ₩5.69 Billion KRW
Based on the latest financial reports, 308430 (308430) has total liabilities worth ₩5.69 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
308430 - Total Liabilities Trend (2022–2024)
This chart illustrates how 308430's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
308430 Competitors by Total Liabilities
The table below lists competitors of 308430 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Designer Brands Inc
NYSE:DBI
|
USA | $1.75 Billion |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
China | CN¥45.68 Million |
|
Westwing Group AG
F:WEW
|
Germany | €129.20 Million |
|
Beijing Tong Ren Tang Chinese Medicine Company Limited
PINK:BJTRF
|
USA | $312.26 Million |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
China | CN¥469.76 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
USA | $6.16 Million |
|
Washington Real Estate Investment Trust
F:WRI
|
Germany | €777.68 Million |
|
Mega-info Media Co.Ltd.
SHE:301102
|
China | CN¥1.31 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down 308430's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 308430's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 308430 (2022–2024)
The table below shows the annual total liabilities of 308430 from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩4.83 Billion | +25.59% |
| 2023-12-31 | ₩3.85 Billion | -47.28% |
| 2022-12-31 | ₩7.30 Billion | -- |